Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

A legfontosabb adatok

Ki végzi
OHSU Knight Cancer Institute
Hol
Portland (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
4 fő vett részt
Kezdés
2023. márc. 1.
Befejezés
2024. júl. 10.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Botulinum Toxin Type A
A regiszteradat frissítve
2025. május 13.
Miért állt le
low enrollment

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant scheduled for elective distal pancreatectomy or radical antegrade modular pancreatosplenectomy (RAMPS), via open or laparoscopic technique
  • Participant >= 18 years of age
  • Ability to understand nature and individual consequences of clinical trial
  • Written informed consent from participant or legally authorized representative
  • For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention

Ki nem vehet részt

  • Prior BTX administration
  • Known hypersensitivity to any BTX preparation or to any of the components in the formulation
  • Infection at the proposed injection site, including cholangitis
  • Serious cardiovascular disease (e.g., myocardial infarction in the past year, New York Heart Association [NYHA] III/IV congestive heart failure, unstable angina)
  • Neuromuscular or any neurological disease with associated increased risk for a participant undergoing BTX injection
  • Any condition that could result in undue risk for the participant and/or influence outcome measures (in the opinion of the investigator)
  • Creatinine clearance < 30 mL/min
  • Anatomy incompatible with planned intervention (e.g., Roux-en-Y gastric bypass, distal gastrectomy with Roux-en-Y or Billroth II reconstruction)
  • Acute pancreatitis within 2 weeks of planned study intervention
  • American Society of Anesthesiologists (ASA) score > III
  • Liver cirrhosis (of any Child-Pugh grade)
  • Inability to obtain informed consent due to comprehension or language barrier
  • Inability to comply with study and/or follow-up procedures
  • Pregnancy or lactation

Helyszínek itt: Egyesült Államok

  • OHSU Knight Cancer InstitutePortland, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase II trial studies the effect of botulinum toxin (Botox) in preventing postoperative pancreatic fistula after distal pancreatectomy. Postoperative pancreatic fistula (POPF) is a known risk of distal pancreatic surgery, in which leakage of pancreatic digestive liquids causes internal swelling that can be painful (termed inflammation). A valve-like muscle, called the Sphincter of Oddi, opens and closes, controlling the flow of digestive liquids from the liver (bile) and pancreas (pancreatic juice) to the small intestine (duodenum). After surgery, the Sphincter of Oddi may act to block the flow of normal pancreatic secretions, causing secretions to leak into the abdomen resulting in POPF. Botox is a drug that can cause paralysis of muscles. Giving an injection of Botox into the sphincter of Oddi before distal pancreatic surgery may reduce leakage of digestive fluids and potential POPF.

A vizsgálat csoportja

  • Treatment of POPF (botulinum toxin type A)A vizsgált kezelés

    Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.

    Kezelés: Botulinum Toxin Type A

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II Trial of Pre-Operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
A regiszteradat frissítve
2025. május 13.